Stallergenes Greer is a global biopharmaceutical company leading innovation in allergen immunotherapy (AIT) and providing allergy solutions around the world.
Stallergenes Greer offers a comprehensive approach to allergic diseases by providing a wide range of products to allergy specialists; from diagnostic tests to allergen immunotherapy.
With a strong focus on innovation, Stallergenes Greer offers unparalleled expertise in the field of allergens and makes an important contribution to the development of allergen immunotherapy offering allergy sufferers increasingly innovative and customized solutions.
COVID-19 is currently affecting communities across the globe due to the spread of the Coronavirus. Stallergenes Greer is reinforcing its commitment to fulfilling its mission and providing patients with access to its allergy immunotherapy solutions.
Stallergenes Greer has taken all the necessary actions to protect the health and safety of its employees, in line with the most up-to-date recommendations from public health authorities. This includes remote working, restricting travel and visits to healthcare professionals. We are diligently ensuring our manufacturing and supply facilities such that patients continue to receive their treatments on time, and we will continue to take the necessary measures to secure reliable supply of our products as the situation evolves.
We remain committed to our purpose and to delivering personalised allergy immunotherapy solutions to our patients in these challenging times. Although we are limiting in-person interactions, we remain fully available for our healthcare professionals and patients via digital technology to ensure support and access to our products.
Stallergenes Greer would like to recognize the dedication of its teams and thank all of the people working on the front lines to reduce exposure to the virus and keep our families and communities safe.
Read more about COVID-19 UPDATE for Australian healthcare professionals
